UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): AUGUST 30, 2004
                                                          _______________

                                  GENEMAX CORP.
                                  _____________
               (Exact name of registrant as specified in charter)

        NEVADA                             0-27239              88-0277072
________________________________________________________________________________
(State or other jurisdiction      (Commission File Number)     (IRS Employer
      of incorporation)                                      Identification No.)

  1681 CHESTNUT STREET, SUITE 400, VANCOUVER, BRITISH COLUMBIA, CANADA V6J 4M6
  ____________________________________________________________________________
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (604) 331-0400
                                                           ______________

                                 NOT APPLICABLE.
                                 _______________
         (Former name or former address, if changed since last report.)

Check the appropriate box below of the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02         APPOINTMENT OF NEW OFFICER

         Effective August 30, 2004, GeneMax Corp. (the "Corporation")  appointed
Konstantine Sarafis the Chief Operating Officer of the Corporation.

         Mr.  Sarafis  has  experience  in  building,  operating  and  mentoring
biotechnology companies. Since 2002, Mr. Sarafis has been a full-time consultant
to  emerging  biotechnology  companies  and  academic  institutions  wishing  to
commercialize new technologies.  Prior to his work as a consultant,  Mr. Sarafis
was  the  Chief  Executive   Officer,   President  and  cofounder  of  Interomex
Biopharmaceuticals  Inc.,  where he was  involved in arranging  venture  capital
financing  and  operating  all aspects of the  business.  Prior to entering  the
biotechnology  sector, Mr. Sarafis was a researcher at the University of British
Columbia  ("UBC") in the  Division  of Medical  Microbiology.  Mr.  Sarafis  has
experience in managing intellectual property, licensing, finance, and marketing.
Mr. Sarafis studied  genetics at The University of British  Columbia and biology
at the University of Guelph in their undergraduate programs.

         The  Corporation  also entered into a  Consulting  and  Non-Competition
Agreement with Mr. Sarafis,  pursuant to which Mr. Sarafis will earn a daily fee
of $1000  (Canadian).  Further,  Mr.  Sarafis  was  granted  options to purchase
100,000 shares of the  Corporation's  common stock at an exercise price of $0.50
per share.

         A copy of the press release  announcing  Mr.  Sarafis'  appointment  is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01         EXHIBITS

DESIGNATION       DESCRIPTION
___________       ___________
99.1              Press Release dated August 30, 2004

                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          GENEMAX CORP.

Date:  September 1, 2004                  By: /s/ RONALD HANDFORD
                                              _________________________________
                                              Ronald Handford, Chief Executive
                                              Officer

                                                                    EXHIBIT 99.1

GENEMAX CORP. APPOINTS KONSTANTINE SARAFIS AS CHIEF OPERATING OFFICER

VANCOUVER,  Canada,  August 30th,  2004/ Canada NewsWire / -- GeneMax Corp. (OTC
Bulletin Board: GMXX;  Frankfurt:  GX1) GeneMax announced today that Konstantine
Sarafis has been appointed as its Chief Operating Officer (COO), effective as of
August  30th,  2004.  Mr.  Sarafis  will be  responsible  for  the  development,
coordination  and execution of the company's  operations,  as well as developing
opportunities for industry partnerships, marketing and financing.

Ronald L. Handford,  President & CEO of GeneMax, stated, "Mr. Sarafis' extensive
experience  in  the  biotech  sector  will  provide  outstanding   guidance  for
implementing  our  operational  plan.  This will support the  achievement of the
company's clinical and strategic development objectives.  We expect Mr. Sarafis'
appointment  will  accelerate  the  advancement  to clinical  trials of our lead
product,  the TAP-1  (Transporters  Associated with Antigen  Processing)  cancer
vaccine, and will help us develop a pipeline of related  immunotherapy  products
through our assay technologies and strategic industry partnerships."

Mr. Sarafis said, "The  technologies that GeneMax has under license are exciting
and innovative. These new therapeutics harness the power of the immune system to
fight  cancer and other  disease.  I am  looking  forward  to  implementing  and
executing GeneMax's strategic plan."

Mr.  Sarafis is an  experienced  executive  with a 13 year  history of building,
operating and mentoring  biotechnology  companies.  He founded two biotechnology
companies, the most recent being, Interomex Biopharmaceuticals Inc. where he was
involved  in  arranging  venture  capital  financing  and running all aspects of
business operations from 1998 through 2002. More recently Mr. Sarafis has been a
full-time   consultant   to  emerging   biotechnology   companies  and  academic
institutions  wishing to commercialize new  technologies.  Prior to entering the
biotechnology  sector,  Mr.  Sarafis was a researcher  at UBC in the division of
Medical   Microbiology.   Mr.  Sarafis  has  extensive  experience  in  managing
intellectual property,  licensing,  finance, as well as marketing and he is well
versed in corporate governance issues.

ABOUT GENEMAX CORP.:  GeneMax Corp. is a biotechnology  company  specializing in
the  discovery  and  development  of  immunotherapeutics  for the  treatment and
eradication  of  cancer,   therapies  for  infectious  diseases  and  autoimmune
disorders  and  prevention  of transplant  tissue  rejection.  The Company is in
production of its TAP cancer vaccine in  preparation  for a Phase I/IIa clinical
trial,  expected  to begin in  mid-2005.  The proof of  principle  for the TAP-1
vaccine  was  established  in mice  bearing  metastatic  small cell lung  cancer
tumors.  This study was published in Nature  Biotechnology (Vol. 18, pp 515-520,
May 2000). In recent developments,  research conducted at McMaster University in
Hamilton,  Ontario and The University of British  Columbia showed that GeneMax's
TAP-1  vaccine  technology  was able to produce  an  effective  immune  response
against  melanoma,  a form of skin cancer,  in mouse  models of the disease,  as
published in Journal of Immunology (reference 1;172(9):5200-5205, May 1, 2004).

For further information:
________________________________________________________________________________
CONTACT:  KENDRA PAYNE
________________________________________________________________________________
Phone: Toll Free (866) 872-0077 or (604) 714-1225    Fax: (604) 331-0877
GeneMax Corp. - Suite 400 - 1681 Chestnut Street, Vancouver B.C. Canada V6J 4M6
Stock  Exchange  Information:  (Symbol:  OTCBB - GMXX,  Symbol  FWB - GX1,  WKN:
645096,  ISN: US36870Q1031)
________________________________________________________________________________

SAFE HARBOR STATEMENT
THIS NEWS  RELEASE  INCLUDES  FORWARD-LOOKING  STATEMENTS  WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM ACT OF 1995.  Except for the  historical
information  presented  herein,  matters discussed in this press release contain
forward-looking  statements that are subject to certain risks and  uncertainties
that could cause actual results to differ  materially  from any future  results,
performance or achievements expressed or implied by such statements.  Statements
that are not  historical  facts,  including  statements  that are  preceded  by,
followed by, or that include such words as "estimate,"  "anticipate," "believe,"
"plan" or "expect" or similar statements are forward-looking  statements.  RISKS
AND  UNCERTAINTIES  FOR  GENEMAX  CORP.  INCLUDE  BUT ARE NOT  LIMITED THE RISKS
ASSOCIATED WITH PRODUCT  DISCOVERY AND DEVELOPMENT AS WELL AS THE RISKS SHOWN IN
GENEMAX'S  MOST RECENT  ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM
TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE  INFORMATION  REGARDING GENEMAX.  OTHER
RISKS INCLUDE risks associated with obtaining  government grants, the success of
preclinical  and  clinical   trials,   the  progress  of  research  and  product
development  programs,  the regulatory approval process,  competitive  products,
future capital requirements,  and GENEMAX'S ability and level of support for ITS
research  ACTIVITIES.  There  can be no  assurance  that  GENEMAX'S  development
efforts  will  succeed,  that such  products  will receive  required  regulatory
clearance,  or that even if such regulatory  clearance were received,  that such
products would ultimately  achieve  commercial  success.  GENEMAX  disclaims any
intent or obligations to update these forward-looking statements."